ClearPoint Neuro/$CLPT
1D1W1MYTD1Y5YMAX
Capital at risk
About ClearPoint Neuro
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
- Ticker
- $CLPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 172
- Headquarters
- Solana Beach, United States
- Website
- www.clearpointneuro.com
ClearPoint Neuro Metrics
BasicAdvanced
$422M
-
-$1.18
1.27
-
Price and volume
Market cap
$422M
Beta
1.27
52-week high
$30.10
52-week low
$8.27
Average daily volume
535K
Financial strength
Current ratio
4.745
Quick ratio
3.754
Long term debt to equity
5.916
Total debt to equity
5.934
Interest coverage (TTM)
-6.07%
Profitability
EBITDA (TTM)
-28.211
Gross margin (TTM)
62.61%
Net profit margin (TTM)
-81.76%
Operating margin (TTM)
-69.17%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-24.43%
Return on equity (TTM)
-226.52%
Valuation
Price to revenue (TTM)
9.568
Price to book
39.15
Price to tangible book (TTM)
-43.89
Price to free cash flow (TTM)
-12.928
Free cash flow yield (TTM)
-7.74%
Free cash flow per share (TTM)
-1.07
Growth
Revenue change (TTM)
25.86%
Earnings per share change (TTM)
47.79%
3-year revenue growth (CAGR)
24.89%
10-year revenue growth (CAGR)
23.18%
3-year earnings per share growth (CAGR)
11.68%
10-year earnings per share growth (CAGR)
-6.41%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
Analyst projections of the future price of ClearPoint Neuro stock.
Bulls say / Bears say
Record Q1 2026 revenue of $12.1 million, a 43% YoY increase, beat analyst estimates and highlights strong momentum from IRRAflow integration and expanded device placements. (Reuters)
Gross margin expanded to 64% in Q1 2026 from 60% in Q1 2025, reflecting operational efficiencies and lower inventory write-offs. (Reuters)
Multiple biopharma partners received positive FDA feedback on BLA submissions and the first GLP statement of work was signed at the new CAL facility, diversifying service offerings and bolstering future revenue streams. (ClearPoint Neuro)
Biologics and drug delivery revenue dropped 15% YoY to $4.0 million in Q2 2026, underscoring segment volatility driven by lumpy orders. (ClearPoint Neuro)
Operating expenses rose 51% YoY to $17.0 million in Q2 2026, widening the operating loss to $10.2 million and increasing cash burn amid integration and capacity investments. (ClearPoint Neuro)
2026 revenue guidance was lowered from $52–56 million to $48–52 million after Q2 results, reflecting moderated growth expectations and prioritization of clinical support over traditional sales expansion. (ClearPoint Neuro)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
Upcoming events
No upcoming events
ClearPoint Neuro News
AllArticlesVideos
ClearPoint Neuro Q2 Earnings Call Highlights
MarketBeat2 months ago
ClearPoint Neuro Reports Second Quarter 2026 Results
Accesswire2 months ago
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
Accesswire2 months ago
Funds containing ClearPoint Neuro
Fund name | Fund size | $CLPT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.